MRNA Now Carries A 12-Month Price Target Of $506.00.
$Moderna, Inc.(MRNA)$’s traded shares stood at 1.99 million during the latest session, with the company’s beta value hitting 1.64. At the last check today, the stock’s price was $144.43, to imply an increase of 6.36% or $8.63 in intraday trading. The MRNA share’s 52-week high remains $497.49, putting it -244.45% down since that peak but still an impressive 17.6% since price per share fell to its 52-week low of $119.01. The company has a valuation of $56.84B, with an average of 5.65 million shares in intraday trading volume over the past 10 days and average of 6.86 million shares over the past 3 months.
Analysts have given a consensus recommendation of an Overweight for Moderna Inc. (MRNA), translating to a mean rating of 2.50. Of 19 analyst(s) looking at the stock, 1 analyst(s) give MRNA a Sell rating. 3 of those analysts rate the stock as Overweight while 10 advise Hold as 5 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at $4.74.
Moderna Inc. (NASDAQ:MRNA) trade information
After registering a 6.36% upside in the latest session, Moderna Inc. (MRNA) has traded red over the past five days. The stock hit a weekly high of 144.23 this Thursday, 05/26/22, jumping 6.36% in its intraday price action. The 5-day price performance for the stock is -5.29%, and -4.65% over 30 days. With these gigs, the year-to-date price performance is -46.53%. Short interest in Moderna Inc. (NASDAQ:MRNA) saw shorts transact 17.06 million shares and set a 2.64 days time to cover.
Analysts on Wall Street suggest a consensus price target of $218.38, implying an increase of 33.86% to the stock’s recent value. The extremes give us $80.00 and $506.00 for target low and target high price respectively. As such, MRNA has been trading -250.34% off suggested target high and 44.61% from its likely low.
Moderna Inc. (MRNA) estimates and forecasts
Looking at statistics comparing Moderna Inc. share performance against respective industry, we note that the company has underperformed competitors. Moderna Inc. (MRNA) shares are -50.33% down over the last 6 months, with its year-to-date growth rate lower than industry average at -3.82% against 0.50%. Revenue is forecast to shrink -26.60% this quarter before falling -6.50% for the next one. The rating firms project that company’s revenue will grow 19.10% compared to the previous financial year.
Revenue forecast for the current quarter as set by 11 analysts is $4.23 billion. Meanwhile, for the quarter ending Sep 2022, a total of 11 analyst(s) estimate revenue growth to $6.01 billion.Earnings reports from the last fiscal year show that sales brought in $4.35 billion and $6.21 billion respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -2.90% before dropping -3.10% in the following quarter.
MRNA Dividends
Moderna Inc. has its next earnings report out between August 03 and August 08. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Moderna Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Moderna Inc. (NASDAQ:MRNA)’s Major holders
Moderna Inc. insiders hold 9.43% of total outstanding shares, with institutional holders owning 64.17% of the shares at 70.85% float percentage. In total, 64.17% institutions holds shares in the company, led by Baillie Gifford and Company. As of Mar 30, 2022, the company held over 45.63 million shares (or 11.47% of shares), all amounting to roughly $7.86 billion.
The next major institution holding the largest number of shares is Blackrock Inc. with 28.67 million shares, or about 7.21% of shares outstanding. As of the market price on Mar 30, 2022, these shares were worth $4.94 billion.
We also have Vanguard International Growth Fund and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Moderna Inc. (MRNA) shares. Going by data provided on Feb 27, 2022, Vanguard International Growth Fund holds roughly 9.9 million shares. This is just over 2.49% of the total shares, with a market valuation of $1.52 billion. Data from the same date shows that the other fund manager holds a little less at 9.79 million, or 2.46% of the shares, all valued at about 2.49 billion.
source: marketingsentinel
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Good